These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 35170015)

  • 1. Mechanistic modelling of enzyme-restoration effects of new recombinant liver-targeted proteins in acute intermittent porphyria.
    Vera-Yunca D; Córdoba KM; Parra-Guillen ZP; Jericó D; Fontanellas A; Trocóniz IF
    Br J Pharmacol; 2022 Jul; 179(14):3815-3830. PubMed ID: 35170015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biochemical characterization of porphobilinogen deaminase-deficient mice during phenobarbital induction of heme synthesis and the effect of enzyme replacement.
    Johansson A; Möller C; Fogh J; Harper P
    Mol Med; 2003; 9(9-12):193-9. PubMed ID: 15208740
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Porphobilinogen deaminase over-expression in hepatocytes, but not in erythrocytes, prevents accumulation of toxic porphyrin precursors in a mouse model of acute intermittent porphyria.
    Unzu C; Sampedro A; Mauleón I; Vanrell L; Dubrot J; de Salamanca RE; González-Aseguinolaza G; Melero I; Prieto J; Fontanellas A
    J Hepatol; 2010 Mar; 52(3):417-24. PubMed ID: 19815305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Computational disease model of phenobarbital-induced acute attacks in an acute intermittent porphyria mouse model.
    Vera-Yunca D; Serrano-Mendioroz I; Sampedro A; Jericó D; Trocóniz IF; Fontanellas A; Parra-Guillén ZP
    Mol Genet Metab; 2019 Nov; 128(3):367-375. PubMed ID: 30639045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
    Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
    Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renal failure affects the enzymatic activities of the three first steps in hepatic heme biosynthesis in the acute intermittent porphyria mouse.
    Unzu C; Sampedro A; Sardh E; Mauleón I; Enríquez de Salamanca R; Prieto J; Salido E; Harper P; Fontanellas A
    PLoS One; 2012; 7(3):e32978. PubMed ID: 22412963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria.
    D'Avola D; López-Franco E; Sangro B; Pañeda A; Grossios N; Gil-Farina I; Benito A; Twisk J; Paz M; Ruiz J; Schmidt M; Petry H; Harper P; de Salamanca RE; Fontanellas A; Prieto J; González-Aseguinolaza G
    J Hepatol; 2016 Oct; 65(4):776-783. PubMed ID: 27212246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety, pharmacokinetics and pharmocodynamics of recombinant human porphobilinogen deaminase in healthy subjects and asymptomatic carriers of the acute intermittent porphyria gene who have increased porphyrin precursor excretion.
    Sardh E; Rejkjaer L; Andersson DE; Harper P
    Clin Pharmacokinet; 2007; 46(4):335-49. PubMed ID: 17375984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant porphobilinogen deaminase targeted to the liver corrects enzymopenia in a mouse model of acute intermittent porphyria.
    Córdoba KM; Serrano-Mendioroz I; Jericó D; Merino M; Jiang L; Sampedro A; Alegre M; Corrales F; Garrido MJ; Martini PGV; Lanciego JL; Prieto J; Berraondo P; Fontanellas A
    Sci Transl Med; 2022 Jan; 14(627):eabc0700. PubMed ID: 35020410
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatocyte transplantation ameliorates the metabolic abnormality in a mouse model of acute intermittent porphyria.
    Yin Z; Wahlin S; Ellis EC; Harper P; Ericzon BG; Nowak G
    Cell Transplant; 2014; 23(9):1153-62. PubMed ID: 23582197
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adenoviral-mediated expression of porphobilinogen deaminase in liver restores the metabolic defect in a mouse model of acute intermittent porphyria.
    Johansson A; Nowak G; Möller C; Blomberg P; Harper P
    Mol Ther; 2004 Aug; 10(2):337-43. PubMed ID: 15294180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease pharmacokinetic-pharmacodynamic modelling in acute intermittent porphyria to support the development of mRNA-based therapies.
    Parra-Guillen ZP; Fontanellas A; Jiang L; Jericó D; Martini P; Vera-Yunca D; Hard M; Guey LT; Troconiz IF
    Br J Pharmacol; 2020 Jul; 177(14):3168-3182. PubMed ID: 32133631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variations in porphobilinogen and 5-aminolevulinic acid concentrations in plasma and urine from asymptomatic carriers of the acute intermittent porphyria gene with increased porphyrin precursor excretion.
    Floderus Y; Sardh E; Möller C; Andersson C; Rejkjaer L; Andersson DE; Harper P
    Clin Chem; 2006 Apr; 52(4):701-7. PubMed ID: 16497943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.
    Solares I; Jericó D; Córdoba KM; Morales-Conejo M; Ena J; Enríquez de Salamanca R; Fontanellas A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma porphobilinogen as a sensitive biomarker to monitor the clinical and therapeutic course of acute intermittent porphyria attacks.
    Sardh E; Harper P; Andersson DE; Floderus Y
    Eur J Intern Med; 2009 Mar; 20(2):201-7. PubMed ID: 19327613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria.
    Lindberg RL; Porcher C; Grandchamp B; Ledermann B; Bürki K; Brandner S; Aguzzi A; Meyer UA
    Nat Genet; 1996 Feb; 12(2):195-9. PubMed ID: 8563760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex differences in vascular reactivity in mesenteric arteries from a mouse model of acute intermittent porphyria.
    Pulgar VM; Yasuda M; Gan L; Desnick RJ; Bonkovsky HL
    Mol Genet Metab; 2019 Nov; 128(3):376-381. PubMed ID: 30639047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Non-viral delivery of the porphobilinogen deaminase cDNA into a mouse model of acute intermittent porphyria.
    Johansson A; Nowak G; Möller C; Harper P
    Mol Genet Metab; 2004 May; 82(1):20-6. PubMed ID: 15110317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families.
    Kauppinen R; von und zu Fraunberg M
    Clin Chem; 2002 Nov; 48(11):1891-900. PubMed ID: 12406973
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
    Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
    Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.